A Comparison of the Oral Anticoagulant LY517717 Difumarate to Subcutaneous Enoxaparin for the Prevention of Venous Thromboembolic Events (VTE) Post-Total Hip Replacement (THR) and Post-Total Knee Replacement (TKR) Surgery.
Phase of Trial: Phase II
Latest Information Update: 19 Dec 2008
At a glance
- Drugs Enoxaparin sodium; LY 517717
- Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 19 Dec 2008 New trial record.